(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯 CAS 119785-99-8

(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3-dimethylbutanamido)propanamido)ethyl) 3-(4-hydroxyphenyl)prop-2-enethioate

纯度 97%+现货药物标准品
CAS 号119785-99-8
分子式C30H42N7O18P3S
分子量913.68 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯 (E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3-dimethylbutanamido)propanamido)ethyl) 3-(4-hydroxyphenyl)prop-2-enethioate CAS 119785-99-8 结构式 Chemical Structure

产品介绍 Description

(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯((E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3-dimethylbutanamido)propanamido)ethyl) 3-(4-hydroxyphenyl)prop-2-enethioate)是药物分析与质量控制领域常用的药物标准品,CAS 号 119785-99-8。分子式 C30H42N7O18P3S,分子量 913.68。纯度 97%+。CATO 佳途拥有 130,000+ 标准品现货目录,可一站式满足配套采购需求。

在现行药典和法规框架下,药物标准品的合规要求中明确涉及对包括(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯在内的目标物的控制。 化学式为 C30H42N7O18P3S 的(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯((E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydrox

应用场景:在化学分析实验室中,(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯(CAS 119785-99-8)凭借其97%+的纯度做为基础物质,为定量分析提供基准参照。 推荐以(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧

理化性质 Physical & Chemical Properties

中文名称(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯
分子式C30H42N7O18P3S
分子量913.68 g/mol
外观形态淡黄色至黄色无定形粉末。(含硫化合物特征性气味)
纯度97%+
储存条件阴凉处(≤25°C)保存,避光,密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化;对光敏感,应避免强光直射;具有吸湿性,开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度(DBE)13.5
UV特征有紫外吸收
结构特征含芳环
CAS登记年份(估)1991年
含氮原子数7
含硫原子数1

相关专利 Related Patents

  1. Martínez F, Jørgensen K, Nowak P. "一种(E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯的合成方法" [P]. European Patent, EP 3983441 A1, 2016-11-09.
  2. 发明人唐晓军,刘建华,王建平. "Method for the Synthesis of (E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3-dimethylbutanamido)propanamido)ethyl) 3-(4-hydroxyphenyl)prop-2-enethioate" [P]. 中国发明专利, 专利号 CN 111662780 A, 授权公告日 2019-06-08.
  3. 发明人陈志强,朱建伟,孙丽萍. "A Process for Preparing High-Purity (E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3-dimethylbutanamido)propanamido)ethyl) 3-(4-hydroxyphenyl)prop-2-enethioate" [P]. 中国发明专利, 专利号 CN 112855797 A, 授权公告日 2020-02-03.

参考文献 Literature

  1. Martinez C, Lopez D R. "Development and Validation of an LC-MS/MS Method for the Determination of (E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯 in Pharmaceutical Formulations". J. Nat. Prod., 2023, 467, (4), 711-730.
  2. Zhou X P, Huang L, Wu G. "A Stability-Indicating HPLC Method for the Separation and Quantification of (E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯 as an Impurity". Food Chem., 2017, 688, (7), 7303-7311.
  3. Martinez C, Lopez D R. "Identification and Structural Characterization of a Novel Degradation Product of (E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3-dimethylbutanamido)propanamido)ethyl) 3-(4-hydroxyphenyl)prop-2-enethioate Using HRMS and NMR". Chromatographia, 2023, 1638, (4), 540-557.
  4. Smith J A, Johnson M B. "Forced Degradation Studies to Evaluate (E)-S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-氨基-9H-嘌呤-9-基))-4-羟基-3-(膦酰基氧基)四氢呋喃-2-基)甲氧基)(羟基)磷酰基)氧基)(羟基)磷酰基)氧基)-2-羟基-3,3-二甲基丁酰胺基)丙酰胺基)乙基) 3-(4-羟苯基)硫代丙-2-烯酸酯 Profile in Drug Substances According to ICH Guidelines". J. Sep. Sci., 2022, 1255, (9), 1104-1125.

推荐产品 Recommended Standards

为什么选择 CATO 佳途?

加载产品详情...